Jefferies Financial Group Reaffirms “Hold” Rating for Prestige Consumer Healthcare (NYSE:PBH)

Jefferies Financial Group reissued their hold rating on shares of Prestige Consumer Healthcare (NYSE:PBH) in a research note released on Tuesday morning, Benzinga reports. They currently have a $76.00 target price on the stock, up from their previous target price of $70.00.

Separately, DA Davidson upped their target price on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a buy rating in a report on Wednesday, August 28th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of Moderate Buy and an average price target of $94.20.

Prestige Consumer Healthcare Trading Up 0.8 %

Shares of Prestige Consumer Healthcare stock opened at $71.35 on Tuesday. The firm has a market capitalization of $3.54 billion, a PE ratio of 17.11, a price-to-earnings-growth ratio of 2.04 and a beta of 0.48. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90. The company’s fifty day moving average price is $71.22 and its two-hundred day moving average price is $69.64. Prestige Consumer Healthcare has a 52-week low of $56.34 and a 52-week high of $75.80.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.86 by $0.04. The firm had revenue of $267.10 million for the quarter, compared to analyst estimates of $260.54 million. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The business’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.06 EPS. On average, analysts expect that Prestige Consumer Healthcare will post 4.42 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Large investors have recently made changes to their positions in the company. Covestor Ltd grew its holdings in Prestige Consumer Healthcare by 21.6% during the 1st quarter. Covestor Ltd now owns 834 shares of the company’s stock worth $61,000 after acquiring an additional 148 shares during the last quarter. Evergreen Capital Management LLC grew its holdings in Prestige Consumer Healthcare by 5.4% during the 2nd quarter. Evergreen Capital Management LLC now owns 3,143 shares of the company’s stock worth $216,000 after acquiring an additional 160 shares during the last quarter. Miller Howard Investments Inc. NY grew its holdings in Prestige Consumer Healthcare by 2.2% during the 2nd quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock worth $534,000 after acquiring an additional 165 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Prestige Consumer Healthcare by 80.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after acquiring an additional 208 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in Prestige Consumer Healthcare by 42.5% during the 4th quarter. Parallel Advisors LLC now owns 714 shares of the company’s stock worth $44,000 after acquiring an additional 213 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.